Results 91 to 100 of about 226,280 (311)
, 2005 Governed by parasite and host factors and immunoinflammatory responses, the clinical spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions), and disseminated infection (cutaneous, mucosal, or visceral).
Berman, Jonathan D +3 more
core +1 more source
Advances in Microbial Diagnostics: Machine Learning and Nanotechnology for Zoonotic Disease Control
WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 1, January/February 2026.This review highlights how integrating machine learning with nanotechnology enables enhanced diagnostics, personalized treatments, and the prediction of outbreaks for zoonotic diseases, offering a unified framework to advance global health. ABSTRACT Zoonotic diseases pose significant global health threats, with microbial pathogens, including bacteria ...
Narges Lotfalizadeh +8 more
wiley +1 more source
Scientific Reports, 2017 Leishmaniasis is a highly diverse group of diseases caused by kinetoplastid of the genus Leishmania. These parasites are taxonomically diverse, with human pathogenic species separated into two subgenera according to their development site inside the ...
H. Valdivia +10 more
semanticscholar +1 more source
The epidemiology of canine leishmaniasis: transmission rates estimated from a cohort study in Amazonian Brazil [PDF]
, 1997 We estimate the incidence rate, serological conversion rate and basic case reproduction number (R0) of Leishmania infantum from a cohort study of 126 domestic dogs exposed to natural infection rates over 2 years on Marajó Island, Pará State, Brazil.
Courtenay, O. +3 more
core +1 more source
Visceral Leishmaniasis: Kala-azar [PDF]
QJM, 2016 A 30-year-old male from rural northwest India presented to our hospital with fever of 4 weeks duration associated with abdominal pain. He was a farmer by occupation and gave history of sleeping in the open. General physical examination showed pallor and subcentimetric cervical lymphadenopathy.
R V, Nampoothiri +3 more
openaire +2 more sources
European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.Controlled Human Infection Models (CHIMs) offer a powerful approach to accelerate vaccine development for neglected tropical diseases (NTDs). This review highlights scientific and translational advances enabled by CHIMs, with a focus on a novel Leishmania major model.
Vivak Parkash
wiley +1 more source
BMC Research Notes, 2018 Objective Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis.
Md Golam Hasnain +7 more
doaj +1 more source
Immunobiology of visceral leishmaniasis [PDF]
Frontiers in Immunology, 2012 Visceral leishmaniasis (VL), commonly known as kala-azar, is caused by Leishmania donovani and Leishmania infantum (Leishmania chagasi in the Americas). These Leishmania species infect macrophages throughout the viscera, and parasites are typically found in the spleen, liver, and bone marrow.
Kumar, Rajiv, Nylén, Susanne
openaire +3 more sources
Sex in Immune Cells and Parasitic Diseases — A Complex Relationship
Immunological Reviews, Volume 337, Issue 1, January 2026.ABSTRACT Epidemiological studies consistently show that many parasitic diseases affect males more frequently than females. These disparities are multifactorial, arising partly from gender‐specific behaviors that influence exposure risk and health‐seeking practices, especially in low‐ and middle‐income countries. Increasing evidence also highlights that
Barbara Honecker +2 more
wiley +1 more source
Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis
International Journal of Nanomedicine, 2017 Visceral leishmaniasis (VL) is a fatal, vector-borne disease caused by the intracellular protozoa of the genus Leishmania. Most of the therapeutics for VL are toxic, expensive, or ineffective.
Muzamil Y Want +6 more
semanticscholar +1 more source